The user is using dutasteride, oral minoxidil, and topical minoxidil with tretinoin for hair loss. They are considering whether to continue this treatment or opt for a hair transplant for their temples.
A user is frustrated with slow and thin hair regrowth at the temples despite using Minoxidil for six months, along with dermastamping, oiling, vitamins, and exercise. They are seeking advice on why vellus hairs are not thickening.
The conversation is about a user planning to undergo a hair transplant and seeking information on clinics that perform Verteporfin treatment. A user suggests Dr. Barghouthi might offer this service.
The user saw significant hair regrowth using topical minoxidil and finasteride, even on areas not directly treated. They used local Algerian products with 5% minoxidil and 0.1% finasteride and reported no side effects.
The user is discussing hair regrowth after 3.5 months of using finasteride, questioning if the new growth is baby hairs. They compare photos from December to the present to assess progress.
Verteporfin shows promise in donor hair regeneration after 84 days. Combining Finasteride, Minoxidil, and Pyrilutamide with unlimited hair transplants is seen as a potential near-cure for hair loss.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
Small hairs around the hairline may regrow with continued use of minoxidil, finasteride, and ketoconazole. The user is hopeful about hairline improvement.
A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.
The conversation is about the progress of verteporfin in hair loss trials, with users expressing curiosity about its effectiveness and updates. Specific treatments mentioned include FUE (Follicular Unit Extraction) combined with verteporfin, with one reported case of donor area regrowth after a year, and three patients being monitored post-treatment by Dr. Bloxham with monthly updates on YouTube.
The user underwent a second hair transplant for the crown and mid-scalp, achieving good density. They are using minoxidil, finasteride, and biotin, and considering PRP treatments to enhance growth.
High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
OP injured their temple using derma rolling and tretinoin, causing peeling and potential hair follicle damage. Users suggest the injury might be permanent, possibly resulting in scar tissue where hair won't grow.
The user reports improved crown hair regrowth after 5 months of using Dutasteride and Minoxidil, but minimal change in the front/temples. Others suggest waiting 12-18 months for full results and note that temple regrowth is typically slower.
The conversation is about an 18-year-old male considering topical finasteride for hair loss and asking about the effectiveness of topical melatonin for hair regrowth and density. No specific treatments were confirmed to be used.
The user experienced noticeable hair regrowth after using finasteride for 2 years, oral minoxidil for 1 year, and recently starting dermarolling. The right temple shows significant improvement, while the left remains similar.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.
Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.